Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ent-3-Acetoxy-labda-8(17),13-dien-15-oic acid have vasorelaxant and hypotensive actions, the mechanisms underlying the cardiovascular actions of the labdane involve the activation of the endothelial NO-cGMP pathway, the opening of K+ channels and the alteration on Ca2+ mobilization.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 520.00 | |
1 mL * 10 mM (in DMSO) | Inquiry | $ 530.00 |
Description | ent-3-Acetoxy-labda-8(17),13-dien-15-oic acid have vasorelaxant and hypotensive actions, the mechanisms underlying the cardiovascular actions of the labdane involve the activation of the endothelial NO-cGMP pathway, the opening of K+ channels and the alteration on Ca2+ mobilization. |
Source |
Molecular Weight | 362.51 |
Formula | C22H34O4 |
CAS No. | 63399-37-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
3-Acetoxy-8(17),13E-labdadien-15-oic acid 63399-37-1 GPCR/G Protein Membrane transporter/Ion channel Metabolism Calcium Channel Potassium Channel cAMP 3 Acetoxy 8(17),13E labdadien 15 oic acid 3Acetoxy8(17),13Elabdadien15oic acid inhibitor inhibit